IMBiologics
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
IMBiologics develops antibody-based medicines designed to treat autoimmune diseases and cancer, using its proprietary platform for engineering different antibody formats.
The company licenses its drug candidates to pharmaceutical partners rather than commercializing them independently, and it has transferred rights to its lead programs, including a bispecific antibody and a monospecific antibody targeting immune pathways, to partners including Navigator Medicines. Listed on KOSDAQ, Korea's tech-focused small-cap board, it conducts the full drug-development cycle in-house, from target discovery and antibody engineering through preclinical and clinical stages to manufacturing and quality control.
Summary is AI-generated and may contain errors · figures from DART filings
The company holds its drug-development capabilities entirely in-house across dedicated Discovery, CMC, and clinical development units, which it uses to support out-licensing partnerships.
IMBiologics in five facts
What does IMBiologics do?
IMBiologics develops antibody-based medicines designed to treat autoimmune diseases and cancer, using its proprietary platform for engineering different antibody formats.
Where is IMBiologics listed and in which sector?
IMBiologics (Korean name: 아이엠바이오로직스) trades under KRX code 493280 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Biotechnology.
How large is IMBiologics?
Its market capitalisation was US$167M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were IMBiologics's latest annual revenue and operating profit?
For fiscal year 2025, IMBiologics reported revenue of US$8.8M, operating profit of US$224.7K and net income of US$661.8K, per its annual report on DART (data retrieved from DART on 2026-10-02).
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.